CROMA-PHARMA GmbH

In 2023, CROMA-PHARMA GmbH reported total carbon emissions of approximately 8,200,000 kg CO2e. This figure includes 1,082,000 kg CO2e from Scope 1 emissions, which are direct emissions from owned or controlled sources, and 806,000 kg CO2e from Scope 2 emissions, representing indirect emissions from the generation of purchased electricity, steam, heating, and cooling. The company also reported significant Scope 3 emissions, totalling about 6,608,112 kg CO2e, which encompass a wide range of indirect emissions, including those from capital goods, business travel, employee commuting, and purchased goods and services. In comparison, the previous year, 2022, CROMA-PHARMA GmbH's emissions were approximately 11,000,000 kg CO2e, with Scope 1 emissions at 1,081,591 kg CO2e and Scope 2 emissions at 4,516,000 kg CO2e. This indicates a notable reduction in Scope 2 emissions in 2023, reflecting the company's efforts to improve energy efficiency or transition to cleaner energy sources. Despite these figures, CROMA-PHARMA GmbH has not publicly disclosed specific reduction targets or initiatives under the Science Based Targets initiative (SBTi) or other climate pledges. The absence of formal commitments suggests that while the company is actively monitoring its emissions, it may not yet have established a comprehensive strategy for long-term carbon reduction.